Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time...

Area of Science:

• Ophthalmology
• Neonatology
• Pharmacology

Background:

• Retinopathy of prematurity (ROP) treatment is evolving with new therapeutic options.
• Existing treatments like laser therapy are effective but localized.
• Systemic pharmacological treatments require careful evaluation for potential side effects.

Purpose of the Study:

• To review current knowledge on two advanced pharmacological treatments for ROP: insulin-like growth factor-1 (IGF-1) supplementation and anti-vascular endothelial growth factor (anti-VEGF) therapy.
• To discuss the potential future role of these novel therapies in ROP treatment regimens.
• To emphasize the need for clinical studies to assess safety and efficacy.

Main Methods:

• Literature review of current knowledge on IGF-1 supplementation and anti-VEGF treatments for ROP.
• Analysis of the potential benefits and risks of these pharmacological options compared to existing therapies.
• Discussion of the requirements for future clinical trials.

Main Results:

• IGF-1 supplementation and anti-VEGF treatments represent advanced pharmacological options for ROP.
• These therapies may complement or replace existing treatments, but require thorough evaluation.
• Safety considerations and efficacy data from clinical studies are essential for integration into standard care.

Conclusions:

• Novel pharmacological treatments for ROP, including IGF-1 and anti-VEGF, show promise.
• Rigorous clinical evaluation is necessary to establish safety and efficacy in the vulnerable ROP infant population.
• Further research is critical before these interventions can become standard clinical practice for retinopathy of prematurity.